Rothwell, Figg, Ernst & Manbeck

Rothwell, Figg, Ernst & Manbeck, P.C. is an intellectual property boutique firm headquartered in Washington, D.C., with an additional office in Boston, Massachusetts. With approximately 45 attorneys, the firm is recognized by Vault as a "Top 150 Under 150" firm and ranks #7 among "Best Intellectual Property Specialty Law Firms." Chambers USA 2026 also ranks Rothwell Figg for Intellectual Property: Litigation and Media & Entertainment in the District of Columbia, while the 2026 Best Law Firms® guide awarded it a National Tier 1 ranking for Patent Law.

The firm's patent litigation practice demonstrates deep technical expertise across diverse fields, including biotechnology, pharmaceuticals, telecommunications, electronics, computer hardware and software, and medical devices. Rothwell Figg is particularly recognized for its Hatch-Waxman litigation proficiency, having handled over 60 such cases, representing both brand-name innovators and generic drug manufacturers. Their capabilities also extend to complex copyright disputes, including novel cases involving artificial intelligence and media clients.

Rothwell Figg actively represents both plaintiffs and defendants in patent disputes. Of the five tracked appearances, the firm served as counsel for plaintiffs in three cases and for defendants in two, showcasing a balanced approach to litigation. Notable engagements include representing Regeneron Pharmaceuticals, Inc. as plaintiff against Samsung Bioepis Co., Ltd. in a biosimilar patent dispute, which settled in February 2026, allowing Samsung Bioepis to launch its product in the U.S. in January 2027. The firm also represented Regeneron as defendant against Amgen Inc. in a related biosimilar case where a preliminary injunction against Amgen was denied and affirmed on appeal, leading Amgen to launch its biosimilar at-risk in October 2024.

The firm possesses a robust practice before the Patent Trial and Appeal Board (PTAB), having been counsel for PTAB proceedings in four tracked cases and handling over 60 Inter Partes Reviews (IPRs). Key partners with significant involvement in patent litigation include firm co-founder E. Anthony Figg, recognized for his five decades of experience in chemical, pharmaceutical, and biotechnology patent litigation, including inter partes matters. Joseph A. Hynds is a first-chair patent litigator with over 30 years of experience across various technical domains, including pharmaceuticals, and was lead counsel in the Regeneron v. Amgen case. Brett A. Postal brings extensive experience in patent litigation, post-grant proceedings (including PTAB), and Hatch-Waxman cases, particularly in life sciences technologies. Robert M. Parker, a seasoned litigator with over four decades of experience, focuses on complex technology and regulatory issues, and was lead counsel for DISH Technologies L.L.C.